Clinical Remission of Severe Crohn’s Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b

Glycogen storage disease type 1b (GSD1b) is associated with inflammatory bowel disease and congenital neutropenia. Neutropenia in GSD1b is caused by the accumulation of 1,5-anhydroglucitol-6-phosphate. Empagliflozin is an antidiabetic drug that promotes renal excretion of this metabolite. We report...

Descripción completa

Detalles Bibliográficos
Autores principales: Collen, Lauren V., Newburger, Peter E., Snapper, Scott B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins, Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684244/
https://www.ncbi.nlm.nih.gov/pubmed/38034420
http://dx.doi.org/10.1097/PG9.0000000000000356
_version_ 1785151361359282176
author Collen, Lauren V.
Newburger, Peter E.
Snapper, Scott B.
author_facet Collen, Lauren V.
Newburger, Peter E.
Snapper, Scott B.
author_sort Collen, Lauren V.
collection PubMed
description Glycogen storage disease type 1b (GSD1b) is associated with inflammatory bowel disease and congenital neutropenia. Neutropenia in GSD1b is caused by the accumulation of 1,5-anhydroglucitol-6-phosphate. Empagliflozin is an antidiabetic drug that promotes renal excretion of this metabolite. We report on a patient with refractory GSD1b-associated inflammatory bowel disease who is in clinical remission on empagliflozin monotherapy.
format Online
Article
Text
id pubmed-10684244
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins, Inc.
record_format MEDLINE/PubMed
spelling pubmed-106842442023-11-30 Clinical Remission of Severe Crohn’s Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b Collen, Lauren V. Newburger, Peter E. Snapper, Scott B. JPGN Rep Case Report Glycogen storage disease type 1b (GSD1b) is associated with inflammatory bowel disease and congenital neutropenia. Neutropenia in GSD1b is caused by the accumulation of 1,5-anhydroglucitol-6-phosphate. Empagliflozin is an antidiabetic drug that promotes renal excretion of this metabolite. We report on a patient with refractory GSD1b-associated inflammatory bowel disease who is in clinical remission on empagliflozin monotherapy. Lippincott Williams & Wilkins, Inc. 2023-08-28 /pmc/articles/PMC10684244/ /pubmed/38034420 http://dx.doi.org/10.1097/PG9.0000000000000356 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Collen, Lauren V.
Newburger, Peter E.
Snapper, Scott B.
Clinical Remission of Severe Crohn’s Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b
title Clinical Remission of Severe Crohn’s Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b
title_full Clinical Remission of Severe Crohn’s Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b
title_fullStr Clinical Remission of Severe Crohn’s Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b
title_full_unstemmed Clinical Remission of Severe Crohn’s Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b
title_short Clinical Remission of Severe Crohn’s Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b
title_sort clinical remission of severe crohn’s disease with empagliflozin monotherapy in a pediatric patient with glycogen storage disease type 1b
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684244/
https://www.ncbi.nlm.nih.gov/pubmed/38034420
http://dx.doi.org/10.1097/PG9.0000000000000356
work_keys_str_mv AT collenlaurenv clinicalremissionofseverecrohnsdiseasewithempagliflozinmonotherapyinapediatricpatientwithglycogenstoragediseasetype1b
AT newburgerpetere clinicalremissionofseverecrohnsdiseasewithempagliflozinmonotherapyinapediatricpatientwithglycogenstoragediseasetype1b
AT snapperscottb clinicalremissionofseverecrohnsdiseasewithempagliflozinmonotherapyinapediatricpatientwithglycogenstoragediseasetype1b

Ejemplares similares